New drug combo targets Hard-to-Treat stomach cancer in early trial

NCT ID NCT07325630

Recruiting now Disease control Sponsor: Zhejiang Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding the drug IBI363 to standard chemotherapy can improve outcomes for people with a specific type of locally advanced stomach or gastroesophageal junction cancer (MHC-II-negative). The study will enroll 60 participants who will receive the combination before and after surgery. The main goal is to see how many patients have no cancer cells left in their surgical samples.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI363 combined with chemotherapy (oxaliplatin and capecitabine or S-1)
What this could lead to: If successful, this could lead to a more effective treatment regimen for a specific type of gastric cancer, potentially increasing the chance of complete tumor removal before surgery.
What could go wrong: This is an early-phase, single-center trial with only 60 participants, so results may not apply broadly. The combination therapy may cause significant side effects, and the benefit over standard chemotherapy alone is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IBI363 + CHEMOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IBI363 + CHEMOTHERAPY

Contacts and locations

Locations

Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.